Coverage
Filings
Zealand Pharma on Thursday reported a significant surge in revenue and profit for the first nine months of 2025, driven by its recent partnership with Roche, while also announcing it has paused development of its experimental obesity drug, dapiglutide.
Zealand Pharma's revenue and profit soared in the first half of 2025, a direct result of a major partnership with Roche to develop its new weight-loss drug candidate, petrelintide.
Zealand Pharma on Wednesday reported positive results from a mid-stage study of its experimental obesity drug, dapiglutide, showing an average body weight reduction of 11.6% over 28 weeks.
| 11 Dec 2020 |
| Financial calendar for Zealand Pharma in 2021 | 11 Dec 2020 |
| Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | 9 Dec 2020 |
| Total number of shares and voting rights in Zealand Pharma at November 30, 2020 | 30 Nov 2020 |
| Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | 25 Nov 2020 |
| Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | 20 Nov 2020 |